Communications Biology:NQO1衰减能够加重前列腺癌和肿瘤细胞的可塑性

2020-01-19 AlexYang MedSci原创

NAD (P) H:醌氧化还原酶1(NQO1)能够响应应激来调控细胞命运决定。氧化应激能够支持癌症维持和进展。之前的研究表明了前列腺癌细胞中NQO1(NQO1low)的敲除能够上调促炎细胞因子和激素阻断条件下细胞的生存。最近,有研究人员测试了NQO1low细胞形成肿瘤的能力。研究发现,与NQO1high细胞相比,NQO1low细胞能够形成恶性肿瘤。生物学活检和循环肿瘤细胞表明了前列腺癌的生化复发与

NAD (P) H:醌氧化还原酶1(NQO1)能够响应应激来调控细胞命运决定。氧化应激能够支持癌症维持和进展。之前的研究表明了前列腺癌细胞中NQO1(NQO1low)的敲除能够上调促炎细胞因子和激素阻断条件下细胞的生存。

最近,有研究人员测试了NQO1low细胞形成肿瘤的能力。研究发现,与NQO1high细胞相比,NQO1low细胞能够形成恶性肿瘤。生物学活检和循环肿瘤细胞表明了前列腺癌的生化复发与低水平的NQO1相关。NQO1的沉默能够充分的诱导SMAD介导的TGFβ信号和间充质标记物。TGFβ处理能够减少NQO1水平和诱导与NQO1敲除相似的分子变化。功能上讲,NQO1缺失能够增加氧化应激条件下的迁移和敏感。

最后,研究人员指出,他们的工作阐释了NQO1在抑制前列腺癌细胞的细胞可塑性方面的一个可能的看门人角色。更进一步的是,组合TGFβ信号和NQO1也许可以作为预测生化复发的一个更好的标记。

原始出处:

Dinesh Thapa, Shih-Bo Huang, Amanda R. Muñoz et al. Attenuation of NAD[P]H:quinone oxidoreductase 1 aggravates prostate cancer and tumor cell plasticity through enhanced TGFβ signaling. Communications Biology. 03 Jan 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087651, encodeId=1773208e651eb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 07 04:09:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767737, encodeId=01c01e677373e, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 04 08:09:00 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918969, encodeId=2b9d191896963, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 06 11:09:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313056, encodeId=cc3213130561c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 21 05:09:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040649, encodeId=eabe104064990, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jan 19 17:09:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087651, encodeId=1773208e651eb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 07 04:09:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767737, encodeId=01c01e677373e, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 04 08:09:00 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918969, encodeId=2b9d191896963, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 06 11:09:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313056, encodeId=cc3213130561c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 21 05:09:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040649, encodeId=eabe104064990, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jan 19 17:09:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087651, encodeId=1773208e651eb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 07 04:09:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767737, encodeId=01c01e677373e, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 04 08:09:00 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918969, encodeId=2b9d191896963, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 06 11:09:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313056, encodeId=cc3213130561c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 21 05:09:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040649, encodeId=eabe104064990, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jan 19 17:09:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
    2020-09-06 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087651, encodeId=1773208e651eb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 07 04:09:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767737, encodeId=01c01e677373e, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 04 08:09:00 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918969, encodeId=2b9d191896963, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 06 11:09:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313056, encodeId=cc3213130561c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 21 05:09:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040649, encodeId=eabe104064990, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jan 19 17:09:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087651, encodeId=1773208e651eb, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 07 04:09:00 CST 2020, time=2020-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767737, encodeId=01c01e677373e, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Wed Nov 04 08:09:00 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918969, encodeId=2b9d191896963, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 06 11:09:00 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313056, encodeId=cc3213130561c, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Tue Jan 21 05:09:00 CST 2020, time=2020-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040649, encodeId=eabe104064990, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Jan 19 17:09:00 CST 2020, time=2020-01-19, status=1, ipAttribution=)]
    2020-01-19 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

王伟:2019年前列腺癌研究进展盘点

2019晚期前列腺癌药物进展颇多,其中最具代表性的ASCO重磅研究ENZAMET怎样改变临床实践?TOPARP-B研究结果出炉,Olaparib出现是否预示前列腺癌针对分子亚型的特异性治疗会应用于临床?Sipuleucel-T是FDA第一个批准的用于实体肿瘤的免疫治疗用药,但目前仍然没有免疫检查点抑制剂用于前列腺癌治疗,什么原因限制了免疫治疗在PCa中的应用?mpMRI在PCa诊疗中应用越发广泛,

JAMA:增加蔬菜摄入量与早期前列腺癌患者进展风险

在接受积极监测的早期前列腺癌患者中,增加蔬菜摄入量的行为干预并没有显著降低前列腺癌的进展风险。

朱耀教授:2019年前列腺癌PARP抑制剂治疗的研究进展

2019年,PARP抑制剂在前列腺癌领域的研究进展可谓“收获颇丰”。TOPARP-B、TRITON2和GALAHAD等研究反复证明其在多线治疗后且DNA修复基因缺陷的mCRPC患者中的疗效;而PROFOUND则进一步将奥拉帕利的适用人群扩大至经过新型内分泌治疗且HRR突变的mCRPC患者。本文中,复旦大学附属肿瘤医院朱耀教授为我们回顾了2019年度前列腺癌领域PARP抑制剂治疗的重要研究进展。

Sci Rep:导管型前列腺癌中HoxB13的表达

前列腺导管型恶性肿瘤(DAC)的组织学标准和选择性生物标记相对与腺泡型恶性肿瘤(AAC)来讲几乎还是未知。之前的研究表明了Hox13遗传变异与前列腺癌的致瘤过程相关。最近,有研究人员调查了HoxB13在前列腺癌中的临床病理特征,并比较了前列腺DAC和AAC的临床病理情况。研究人员通过涂片观察,鉴定了相当于格林森等级3和5的DAC表型编译。研究人员分别在训练集中鉴定了46.5%的案例(46/99)具

Clovis的Rubraca超越了多个PARP抑制剂竞争对手,在前列腺癌领域获得FDA的优先审查

FDA刚刚开始对Rubraca(rucaparib)进行为期六个月的优先审查,判决将于5月15日之前完成,用作BRCA1 / 2突变的复发或转移的去势抵抗性前列腺癌(CRPC)成人的单一疗法。BRCA1 / 2基因突变是mCRPC患者最常见的缺陷。

Lancet Oncol:DNA修复基因变异转移去势抵抗性前列腺癌患者中奥拉帕尼治疗研究

转移去势抵抗性前列腺癌富含DNA损伤响应(DDR)基因变异。TOPARP-B试验旨在前瞻性的鉴定DDR基因变异与奥拉帕尼响应在转移去势抵抗性前列腺癌中的相关性。研究有711名患者同意进行靶向筛选,时间为2015年4月1日到2018年8月30日。161名患者具有DDR基因变异,其中98名被随机分配和治疗(每49名进行一种剂量的奥拉帕尼治疗),最后有92名患者的主要治疗终点可以评估(每一种剂量有46名